The Body Covers:
The 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy
San Diego, California
September 27-30, 2002
Friday, September 27
Saturday, September 28
Sunday, September 29
Monday, September 30
Coverage From Other Sources
"It is exciting to see new drug development with agents that appear at least
equally effective as previous agents while less toxic." Edwin DeJesus follows up on the pivotal tenofovir 903 trial first presented at Barcelona in July.
A new randomized study shows that polylactate (NewFill) injections subjectively and objectively improve appearance of HIV-positive patients with facial wasting. Dr. Matthew Leibowitz reports.
A large study on recent deaths from opportunistic infections highlights the continued benefit of therapy, as there were few opportunistic infection-related deaths in those on antiretroviral therapy. Most of the deaths occurred in immigrants who had received no medication or had been diagnosed at a late stage. Click here to read the report from Paul Sax, M.D.
Coverage Provided By:
Throughout ICAAC 2002, an annual meeting of the American Society for Microbiology, The Body provided next-day coverage of individual
presentations and broad overviews of some of the hottest topics in HIV
Click here to view the complete ICAAC program and Web site.
Funding for this coverage is provided, in part, by unrestricted
educational grants from Boehringer Ingelheim Pharmaceuticals, Gilead Sciences and GlaxoSmithKline.
All coverage is © 2002 Body Health Resources Corporation.
Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.